Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.